ENSEMBLE
E854996
ENSEMBLE is the large, global Phase 3 clinical trial that evaluated the safety and efficacy of Johnson & Johnson’s single-dose Ad26.COV2.S COVID-19 vaccine.
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine trial
ⓘ
Phase 3 clinical trial ⓘ clinical trial ⓘ |
| controlType | placebo ⓘ |
| diseaseTarget | COVID-19 NERFINISHED ⓘ |
| doseRegimen | single dose ⓘ |
| efficacyAssessment | monitored incidence of laboratory-confirmed COVID-19 ⓘ |
| endpoint |
assessment of safety profile
ⓘ
prevention of moderate to severe COVID-19 ⓘ prevention of severe COVID-19 ⓘ |
| evaluatedProduct |
Ad26.COV2.S
NERFINISHED
ⓘ
Johnson & Johnson single-dose COVID-19 vaccine ⓘ |
| geographicScope | multiple countries ⓘ |
| interventionType | vaccine ⓘ |
| pathogenTarget | SARS-CoV-2 NERFINISHED ⓘ |
| population | adult participants ⓘ |
| primaryObjective | evaluate efficacy of Ad26.COV2.S against COVID-19 ⓘ |
| regimenCharacteristic | single-shot COVID-19 vaccine ⓘ |
| relatedVaccineName |
Ad26.COV2.S COVID-19 vaccine
GENERATED
ⓘ
Janssen COVID-19 Vaccine GENERATED ⓘ |
| safetyAssessment | monitored adverse events after vaccination ⓘ |
| scope |
global
ⓘ
large ⓘ |
| secondaryObjective |
evaluate immunogenicity of Ad26.COV2.S
ⓘ
evaluate safety of Ad26.COV2.S ⓘ |
| sponsor |
Janssen Pharmaceutical Companies of Johnson & Johnson
NERFINISHED
ⓘ
Johnson & Johnson NERFINISHED ⓘ |
| sponsorCountry | United States NERFINISHED ⓘ |
| sponsorOrganizationType | pharmaceutical company ⓘ |
| sponsorType | industry ⓘ |
| studyDesign |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| therapeuticArea |
infectious diseases
ⓘ
vaccinology ⓘ |
| trialCategory | pivotal efficacy trial ⓘ |
| trialContext | COVID-19 pandemic NERFINISHED ⓘ |
| trialPhase | Phase 3 ⓘ |
| vaccinePlatform | adenoviral vector vaccine ⓘ |
| vaccineVector | recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.